This site is intended only for U.S. Healthcare Providers
Emgality is the #1 prescribed CGRP antibody injection for preventive treatment of migraine* AND has over 90% commercial access.†,1-3
"Emgality is the #1 prescribed CGRP antibody injection for preventive treatment of migraine" and next to it is image in shape of United States and within the US image, text states "And has over 90% commercial access"
Prior authorizations are common when prescribing Emgality®. If patients' health insurance providers require prior authorizations, input patient's insurance information below to identify information you may need.
Requirements vary by plan. Information listed below includes common information that may be requested.
The search capability below is provided by an independent vendor, PrescriberPoint. Lilly USA, LLC does not control or endorse this PrescriberPoint tool. If you choose to use this tool, PrescriberPoint may collect and process your personal information as stated in their privacy policy. Lilly is not responsible for the content on this third-party site, including the privacy policy.
*Based on total prescriptions for subcutaneous calcitonin gene-related peptide (CGRP) antibody injections written after 12/31/2021. Data as of 08/25/2023.
Source: IQVIA database as of 08/25/2023 and is subject to change without notice.
†Over 90% commercial access indicates the subcutaneous CGRP antibody injection on prescription drug plans with pharmacy benefit coverage for the most lives at or equivalent to Preferred, Covered, Specialty, or Generic on all commercial plans for the preventive treatment of migraine.2 Does not take into consideration any restrictions set forth by individual plans. Data as of 09/07/2023.
Source: Managed Markets Insight & Technology (MMIT), LLC as of 09/07/2023 and is subject to change without notice. Please contact the plan or state for the most current information.
"Coverage" includes all statuses at or equivalent to Preferred, Covered, or Specialty for the preventive treatment of migraine.
This information is not a guarantee of coverage or payment (partial or full). Actual benefits are determined by each plan administrator in accordance with its respective policy and procedures.
Employers and employer groups may also offer additional benefit designs, which may be different than described.
This list may not be an exhaustive list of all plans in your area and the coverage of other plans in your area may vary.
The company/plan names listed do not imply their endorsement of Lilly USA, LLC or the product(s) referenced.
Lilly USA, LLC does not endorse any particular plan. Other product and company names mentioned herein are the trademarks of their respective owners.
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
References
Data on File. Lilly USA, LLC. DOF-GZ-US-0190.
Emgality. Prescribing Information. Lilly USA, LLC.
Data on File. Lilly USA, LLC. DOF-GZ-US-0189.
IMPORTANT SAFETY INFORMATION
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.
Hypertension
Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including Emgality, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within 7 days of therapy initiation. Emgality was discontinued in many of the reported cases.
Monitor patients treated with Emgality for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of Emgality is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.
Raynaud’s Phenomenon
Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including Emgality. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred after a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.
Emgality should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.
Emgality is an injectable prescription medicine, available as:
prefilled single-dose pen with 120 mg/mL solution
prefilled single-dose syringe with 120 mg/mL solution
prefilled single-dose syringe with 100 mg/mL solution
